Target- |
Mechanism- |
|
Originator Org.- |
|
|
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Randomized, Double Blind, Lutein Controlled Study of Zeaxanthin and Visual Function in Atrophic Age Related Macular Degeneration Patients
To evaluate if supplementation of zeaxanthin (with or without Lutein) is beneficial to patients with early and moderate Atrophic Age Related Macular Degeneration.
100 Clinical Results associated with Chrysantis, Inc.
0 Patents (Medical) associated with Chrysantis, Inc.
100 Deals associated with Chrysantis, Inc.
100 Translational Medicine associated with Chrysantis, Inc.